Efficacy, Safety and Tolerability of a New 10% Intravenous Immunoglobulin for the Treatment of Primary Immunodeficiencies
We report here the results of a phase 3 study to assess the efficacy, safety, and tolerability of GC5107, a new 10% liquid intravenous immunoglobulin (IVIG) in preventing serious bacterial infections in patients with primary immunodeficiency (ClinicalTrials.gov: NCT02783482). Over a 12-month study p...
Збережено в:
| Автори: | , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Frontiers Media S.A.
2021-07-01
|
| Серія: | Frontiers in Immunology |
| Предмети: | |
| Онлайн доступ: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.707463/full |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|